Company / R&D Expense
Glaukos Corp. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$150.6M
FY2025
5-year range
$101.0M / $150.6M
FY2021-FY2025
Trend
+10.4%
vs FY2024
Sector context
#44 of 105
Health Care
What the data says
At $151M, Glaukos Corp.'s r&d expense ranks #44 of 105 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $11M in FY2018 to $151M in FY2025.
Based on SEC 10-K filings.
$151M in FY2025 with a 5-year CAGR of +12.0%.
Improved from $139M to $151M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +6.9%
- 5-Year CAGR
- +12.0%
- 10-Year CAGR
- -
Sector benchmark
#44 of 105 in Health CareTop 42% of 105This company $150.6M Sector average $284.2M
▼
-47.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.0%, indicating consistent growth.
- In FY2025, r&d expense increased 10.4% year-over-year.
- Ranks #44 out of 105 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $150.6M | +10.4% |
| FY2024 | $136.4M | -1.7% |
| FY2023 | $138.8M | +12.6% |
| FY2022 | $123.3M | +22.1% |
| FY2021 | $101.0M | +18.3% |
| FY2020 | $85.4M | +25.0% |
| FY2019 | $68.3M | +526.3% |
| FY2018 | $10.9M | -72.0% |
| FY2017 | $38.9M | +33.1% |
| FY2016 | $29.2M | +16.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026